Polaryx Therapeutics (PLYX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs).

• Pipeline includes small molecule therapies (PLX-200, PLX-300, PLX-100) and a preclinical gene therapy (PLX-400), targeting multiple LSDs with high unmet need.

• Lead candidate PLX-200 (gemfibrozil) is being advanced through a Phase 2 proof-of-concept basket trial (SOTERIA) for CLN2, CLN3, Krabbe disease, and Sandhoff disease, with trial initiation expected in the first half of 2026.

• Multi-modal approach aims to address both genetic and downstream pathological features of LSDs, leveraging mechanisms such as lysosomal biogenesis, reduction of neuroinflammation, and neuronal support.

• Business model includes leveraging regulatory designations (orphan drug, fast track, rare pediatric disease) and pursuing the 505(b)(2) pathway for accelerated development.

Financial performance and metrics

• No product revenue to date; company has funded operations primarily through equity issuances totaling $21.7 million since inception.

• Net loss of $7.5 million for the nine months ended September 30, 2025, and $30.4 million for the year ended December 31, 2024.

• Accumulated deficit of $98.1 million as of September 30, 2025.

• Cash and cash equivalents of $5.7 million and working capital of $5.3 million as of September 30, 2025.

• Operating expenses primarily driven by research and development, with significant increases in stock-based compensation and consulting fees related to pipeline advancement and advisory services.

• Management expects existing capital to fund operations through the third quarter of 2026; additional capital will be required for continued development.

Use of proceeds and capital allocation

• Company will not receive any proceeds from the resale of shares by registered stockholders in the direct listing.

• All available funds and future earnings are intended to be retained to fund development, commercialization, and growth; no dividends anticipated in the foreseeable future.

• Capital allocation is focused on advancing clinical trials, expanding the pipeline, and supporting operational growth.